Advertisement
Advertisement

JNJ

JNJ logo

Johnson & Johnson

225.33
USD
Sponsored
-5.47
-2.37%
May 29, 16:00 UTC -4
Closed
exchange

After-Market

225.41

+0.08
+0.04%

Johnson & Johnson Profile

About

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.

Info & Links

CEO

J. Duato

Headquarters

ONE JOHNSON & JOHNSON PLZ
NEW BRUNSWICK, NJ 08933, UNITED STATES

Industry

Large Cap Pharmaceuticals

Sector

Medical

Website

http://www.jnj.com

Auditor

PricewaterhouseCoopers LLP

Share holders

108,358

Employees

138,200

Johnson & Johnson Statistics

Valuation Measures

Market Capitalization2

542.62B

Enterprise Value

575.92B

Enterprise Value/EBITDA(ttm)

16.61

Price to Earnings Ratio(ttm)

22.34

Price to Sales(ttm)

6.17

Price to Book(mrq)

7.13

Price to Cash(ytd)

17.09

Profitability

Gross Margin(ttm)

67.85%

Operating Margin(ttm)

27.83%

Profit Margin(ttm)

28.97%

Return on Equity(ttm)

33.04%

Return on Invested Capital(ttm)

22.72%

Return on Assets(ttm)

13.46%

Income Statement

Revenue(ttm)

96.36B

Revenue Per Share(ttm)

40.03

Gross Profit(ttm)

65.36B

EBITDA(ttm)3

34.67B

Net Income Available to Common(ttm)

21.04B

Diluted EPS(ttm)

11.05

Share Statistics

Beta (5Y Monthly)

0.34

52-Week Change

47.83%

S&P 500 52-Week Change

28.22%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

2.41B

Dividend Yield

2.15%

Float4

2.40B

% Held by Insiders

0.16%

% Held by Institutions

69.55%

Balance Sheet

Total Cash(mrq)

22.05B

Total Cash Per Share(mrq)

9.16

Total Debt(mrq)

54.99B

Total Debt/Equity(mrq)

58.78%

Current Ratio(mrq)

1.03%

Quick Ratio(mrq)

0.77%

Book Value Per Share(mrq)

33.86

Cash Flow

Operating Cash Flow Per Share(ytd)

10.10

Free Cash Flow(ytd)

20.42B

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement